Massive ALS GWAS Cements Cytoskeletal Link to Disease
Kinesin mutations may disrupt organelle transport, putting motor neurons at risk.
ALL NEWS
6538 RESULTS
Sort By:
- Most Recent
- Most Commented
NGF Gene Therapy Trial Data Published
No benefit detected in double-blind trial with sham surgical controls.
AAT-AD/PD Focus Meeting 2018- Advances in Alzheimer’s and Parkinson’s Therapies
After Plasma Aβ, Now Plasma P-Tau181 Shows Promise To Block Tau’s Proteopathic Spread, Antibody Must Attack its Mid-Region DIAN and ADNI Data Say Familial and Sporadic AD Converge News From the PET Front: Early Amyloid Networks and Tau Mystery Alzheimer’s
To Block Tau’s Proteopathic Spread, Antibody Must Attack its Mid-Region
The epitope that a therapeutic tau antibody targets determines whether it prevents seeding in cellular assays, raising questions about first-generation antibody trials.
DIAN and ADNI Data Say Familial and Sporadic AD Converge
A comparison of these large data sets shows that while the two forms of Alzheimer’s disease have separate triggers, they follow the same course and are much more similar than different.
News From the PET Front: Early Amyloid Networks and Tau Mystery
At AAT-AD/PD, scientists showed that correlated amyloid patches are an even earlier marker than brain-wide positivity, while others puzzled over why tau signals are lower in older people.
Fighting RAGE No Help to Alzheimer’s Disease Patients
An antagonist to this receptor was trounced in Phase 3 trial.
Alzheimer’s Incidence is Rising, Not Falling, a Researcher Says
A widely popularized finding of shrinking dementia rates is entirely due to less vascular dementia, and is in fact concealing a rise in AD and PD, according to a provocative talk at AAT-AD/PD.
Newborn Neurons in the Adult Brain: Real Deal, or Glial Imposters?
A study reported that new neurons continue to sprout from the human hippocampus well into the golden years, while another claims they all but disappear after childhood.
Is Shape of Aβ an Early Blood Biomarker for Alzheimer’s?
An infrared spectral signature of amyloid β-sheets predicted AD conversion years before diagnosis.
Parkinson’s Treatments Go After Genetic Targets
Researchers at AAT-AD/PD discussed investigational PD treatments that aim to modify disease by hitting genetic risk factors.
Do Immune Responses Promote, or Prevent, Parkinson’s Disease?
In animal models, a PD risk gene revs up the immune system to fight infections, while probiotic bacteria slow α-synuclein aggregation.
Genetics Tie ALS into the Frontotemporal Dementia Spectrum
Massive meta-analysis finds no link with AD or PD.
Will PET Tracer, Monkey Model, Finally Bulk Up Toolbox for Parkinson’s?
At AAT-AD/PD, scientists said an α-synuclein PET tracer is headed into trials. And marmosets model PD behaviors better than rodents. (Spoiler alert: They kick their partners while they sleep.)
JAD Turns 20 with Open-Access Special Issue
Thirty-five reviews cover two decades of Alzheimer’s research.
Current Filters
No filters selected